No Data
No Data
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 P.m. ET
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
OptimizeRx: A Strong Buy on Client Commitments and Growth Potential
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $15
OptimizeRx Continues to Expand Its Strategic Relationship With a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment With Over $10M In-Year Total Value
No Data
No Data